Antineoplastic drugs administered during pregnancy

S. F. Williams, R. L. Schilsky*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations


Cancer is the second leading cause of death in women during their reproductive years. Thus, antineoplastic drugs may be administered to pregnant women. The effects these agents have on the developing fetus depend on the type of agent and the timing of exposure during embryogenesis. In particular, antifolate antimetabolites should be avoided. However, the literature contains many reports of successful fetal outcomes after exposure to other types of agents. The decision to begin antineoplastic therapy must be carefully considered by all physicians and the patient involved. (C) 2000 by W.B. Saunders Company.

Original languageEnglish (US)
Pages (from-to)618-622
Number of pages5
JournalSeminars in Oncology
Issue number6
StatePublished - 2000
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Antineoplastic drugs administered during pregnancy'. Together they form a unique fingerprint.

Cite this